+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID06809764

Evaluating Clinical Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients with HER2-Mutated Metastatic Non-Small Cell Lung Cancer A Prospective Observational Study

Led by Daiichi Sankyo · Updated on 2026-08-18

150

Participants Needed

36

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the real-world effectiveness and safety of Trastuzumab Deruxtecan T-DXd in Chinese patients with locally advanced or metastatic non-small cell lung cancer NSCLC who have HER2 mutations. Although T-DXd is approved and has shown efficacy in clinical trials for NSCLC patients with these mutations, there is limited data on its use outside clinical trial settings in China. This is a non-interventional, observational study where no study drug will be provided or administered by the study team. Participants who have already received T-DXd as part of their routine care, based on their physicians decision, will be enrolled and observed. The study focuses on patients receiving T-DXd as at least a second-line treatment. Participants will be followed for up to approximately two years, during which researchers will collect information on progression-free survival, overall survival, treatment responses, and any treatment-related side effects. Data collection will include assessments by investigators and monitoring of adverse events to evaluate safety and tolerability in a real-world setting.

CONDITIONS

Brief Title

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

Research Team

C

Contact for Clinical Trial Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here